Archive

Neovasc Reducer™ Featured in Peer Reviewed EuroIntervention and PCR Online

Studies demonstrate the Neovasc Reducer™ alleviates refractory angina symptoms   NASDAQ, TSX: NVCN   VANCOUVER, March 3, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory...

Read More

Neovasc Initiates Independent Inquiry into Trading of its Shares

  NASDAQ, TSX: NVCN   Vancouver, Canada, February 11, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced...

Read More

Neovasc Provides Update on Nasdaq Compliance

NASDAQ, TSX: NVCN     VANCOUVER, February 3, 2020, Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today confirms that the...

Read More

Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer™ for Treatment of Refractory Angina

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure   NASDAQ, TSX: NVCN    VANCOUVER, January 28, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive...

Read More